BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Innogen Pharma enters into billion dollar deal with Arcera Life Sciences for GLP-1 therapy

November 20, 2026 | News

Collaboration marks an important step in bringing a China-developed and commercialised innovative GLP-1 therapy to international markets



China-based Innogen Pharmaceuticals has entered into an exclusive licensing and commercialisation agreement with Arcera Life Sciences for the development and commercialisation of its internally developed innovative product Efsubaglutide Alfa, in international markets.

The collaboration represents an important milestone in the international development of Efsubaglutide Alfa and a significant step forward in Innogen's global expansion strategy. It also highlights the potential for China-originated innovation to move beyond domestic commercialization and reach international markets.

Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries within Africa, Eastern Europe, Latin America, and the Middle East, while Innogen retains the relevant rights in the rest of the world. Innogen will receive $38 million in upfront and near-term milestone payments, including a non-refundable upfront payment of $15 million, as well as sales milestone payments and tiered royalties at rates of up to double-digit percentage based on aggregate annual net sales of the Product in the Territory. The total potential deal value is over $1 billion.

Efsubaglutide Alfa is a fusion protein comprising a human GLP-1 analogue and an IgG Fc fragment. It has an average half-life of up to 280 hours across different studies. Clinical studies have shown that monotherapy with Efsubaglutide Alfa reduced HbA1c by 1.1 percentage points after four weeks, with a reduction of up to 2.2 percentage points at Week 24, and that it may also help protect pancreatic beta-cell function.